- Home
- ATCH vs TOVX Comparison
ATCH vs TOVX Comparison
Compare ATCH & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATCH
- TOVX
- Stock Information
- Founded
- ATCH 2022
- TOVX 2001
- Country
- ATCH United States
- TOVX United States
- Employees
- ATCH N/A
- TOVX N/A
- Industry
- ATCH
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- ATCH
- TOVX Health Care
- Exchange
- ATCH Nasdaq
- TOVX Nasdaq
- Market Cap
- ATCH 4.4M
- TOVX 4.7M
- IPO Year
- ATCH N/A
- TOVX 2006
- Fundamental
- Price
- ATCH $0.54
- TOVX $1.18
- Analyst Decision
- ATCH
- TOVX Strong Buy
- Analyst Count
- ATCH 0
- TOVX 1
- Target Price
- ATCH N/A
- TOVX $6.00
- AVG Volume (30 Days)
- ATCH 2.1M
- TOVX 23.5K
- Earning Date
- ATCH 05-27-2025
- TOVX 05-06-2025
- Dividend Yield
- ATCH N/A
- TOVX N/A
- EPS Growth
- ATCH N/A
- TOVX N/A
- EPS
- ATCH 2.67
- TOVX N/A
- Revenue
- ATCH N/A
- TOVX N/A
- Revenue This Year
- ATCH N/A
- TOVX N/A
- Revenue Next Year
- ATCH N/A
- TOVX N/A
- P/E Ratio
- ATCH $0.21
- TOVX N/A
- Revenue Growth
- ATCH N/A
- TOVX N/A
- 52 Week Low
- ATCH $0.49
- TOVX $1.03
- 52 Week High
- ATCH $99.00
- TOVX $12.25
- Technical
- Relative Strength Index (RSI)
- ATCH 28.09
- TOVX 44.04
- Support Level
- ATCH $0.87
- TOVX $1.08
- Resistance Level
- ATCH $1.10
- TOVX $1.21
- Average True Range (ATR)
- ATCH 0.10
- TOVX 0.07
- MACD
- ATCH 0.08
- TOVX 0.00
- Stochastic Oscillator
- ATCH 6.92
- TOVX 57.89
About ATCH AtlasClear Holdings Inc. Common Stock
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and innovative financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.